Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B Biol. Sci. 147, 258–267 (1957).
Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131–144 (2016).
Google Scholar
Marks, Z. R. et al. Properties and functions of the novel type I interferon epsilon. Semin. Immunol. 43, 101328 (2019).
Google Scholar
Marks, Z. R. et al. Interferon-ε is a tumour suppressor and restricts ovarian cancer. Nature 620, 1063–1070 (2023). This is the first report of the suppressive function of IFNε in ovarian cancer.
Google Scholar
Fung, K. Y. et al. Expression of interferon epsilon in mucosal epithelium is regulated by Elf3. Mol. Cell. Biol. 44, 334–343 (2024).
Google Scholar
Liu, Y.-J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275–306 (2005).
Google Scholar
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
Google Scholar
Haynes, N. M., Chadwick, T. B. & Parker, B. S. The complexity of immune evasion mechanisms throughout the metastatic cascade. Nat. Immunol. 25, 1793–1808 (2024). This review highlights the multiple mechanisms of immune escape throughout cancer metastasis.
Google Scholar
Musella, M., Galassi, C., Manduca, N. & Sistigu, A. The yin and yang of type I IFNs in cancer promotion and immune activation. Biology 10, 856 (2021).
Google Scholar
Cheon, H., Wang, Y., Wightman, S. M., Jackson, M. W. & Stark, G. R. How cancer cells make and respond to interferon-I. Trends Cancer 9, 83–92 (2023).
Google Scholar
Chhipa, A. S., Boscaro, V., Gallicchio, M. & Patel, S. The curious case of type I interferon signaling in cancer. Biochim. Biophys. Acta Rev. Cancer 1879, 189204 (2024).
Google Scholar
Yu, Q. et al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep. 11, 785–797 (2015).
Google Scholar
Accardi, G. & Caruso, C. Immune-inflammatory responses in the elderly: an update. Immun. Ageing 15, 11 (2018).
Google Scholar
Pinti, M. et al. Aging of the immune system: focus on inflammation and vaccination. Eur. J. Immunol. 46, 2286–2301 (2016).
Google Scholar
Thomas, R., Wang, W. & Su, D. M. Contributions of age-related thymic involution to immunosenescence and inflammaging. Immun. Ageing 17, 2 (2020).
Google Scholar
Sun, Y., Coppé, J.-P. & Lam, E. W. F. Cellular senescence: the sought or the unwanted? Trends Mol. Med. 24, 871–885 (2018).
Google Scholar
Moiseeva, O., Mallette, F. A., Mukhopadhyay, U. K., Moores, A. & Ferbeyre, G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol. Biol. Cell 17, 1583–1592 (2006).
Google Scholar
Liu, P. et al. Hepatocellular senescence: immunosurveillance and future senescence-induced therapy in hepatocellular carcinoma. Front. Oncol. 10, 589908 (2020).
Google Scholar
Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017).
Google Scholar
Owen, K. L. et al. Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Rep. 21, e50162 (2020). This study highlights the plasticity of IFN signalling throughout cancer dissemination and bone metastasis.
Google Scholar
Truskowski, K., Amend, S. R. & Pienta, K. J. Dormant cancer cells: programmed quiescence, senescence, or both? Cancer Metastasis Rev. 42, 37–47 (2023).
Google Scholar
Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379–1392 (2022). This article highlights how type I IFNs can facilitate epigenetic reprogramming that leads to cancer stemness and therapy resistance.
Google Scholar
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
Google Scholar
Bernardo, A., Cosgaya, J. M., Aranda, A. & Jiménez-Lara, A. M. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis. 4, e479 (2013).
Google Scholar
Apelbaum, A., Yarden, G., Warszawski, S., Harari, D. & Schreiber, G. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell. Biol. 33, 800–814 (2013).
Google Scholar
Thyrell, L. et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 21, 1251–1262 (2002).
Google Scholar
Chawla-Sarkar, M. et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249 (2003).
Google Scholar
Sharma, P. et al. Immune checkpoint therapy — current perspectives and future directions. Cell 186, 1652–1669 (2023).
Google Scholar
Holzgruber, J. et al. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. Nat. Commun. 15, 7165 (2024).
Google Scholar
Bazhin, A. V., Von Ahn, K., Fritz, J., Werner, J. & Karakhanova, S. Interferon-α up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front. Immunol. 9, 2129 (2018).
Google Scholar
Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
Google Scholar
Busselaar, J., Sijbranda, M. & Borst, J. The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer. Immunol. Lett. 270, 106938 (2024).
Google Scholar
Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).
Google Scholar
Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224–1231 (2012).
Google Scholar
Qing, F. & Liu, Z. Interferon regulatory factor 7 in inflammation, cancer and infection. Front. Immunol. 14, 1190841 (2023).
Google Scholar
Zhang, Y. et al. Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. Nat. Immunol. 25, 1858–1870 (2024). This paper demonstrates that DNA methylation inhibitors induce IFN signalling, restore immune control and suppress cancer growth in breast and melanoma tumours.
Google Scholar
Deligianni, E., Papanikolaou, C., Terpos, E. & Souliotis, V. L. Elucidating DNA damage-dependent immune system activation. Int. J. Mol. Sci. 26, 5849 (2025).
Google Scholar
Lopez-Pelaez, M. et al. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation. Oncoimmunology 11, 2117321 (2022).
Google Scholar
Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015). This paper demonstrates how DNMT inhibitors trigger dsRNA sensing and IFN signalling through the upregulation of ERVs.
Google Scholar
Chen, W. et al. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 41, 111647 (2022).
Google Scholar
Sumida, T. S. et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 23, 632–642 (2022).
Google Scholar
Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012).
Google Scholar
Ahmad, S., Alsayed, Y. M., Druker, B. J. & Platanias, L. C. The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J. Biol. Chem. 272, 29991–29994 (1997).
Google Scholar
Uddin, S. et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274, 30127–30131 (1999).
Google Scholar
Goh, K. C., Haque, S. J. & Williams, B. R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18, 5601–5608 (1999).
Google Scholar
Cheon, H., Yang, J. & Stark, G. R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31, 33–40 (2011).
Google Scholar
Hwang, I. et al. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat. Commun. 12, 640 (2021).
Google Scholar
Morris, G., Gevezova, M., Sarafian, V. & Maes, M. Redox regulation of the immune response. Cell. Mol. Immunol. 19, 1079–1101 (2022).
Google Scholar
Ahn, M., Ali, A. & Seo, J. H. Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy. Front. Immunol. 15, 1453886 (2024).
Google Scholar
Zannikou, M., Fish, E. N. & Platanias, L. C. Signaling by type I interferons in immune cells: disease consequences. Cancers 16, 1600 (2024).
Google Scholar
Perez-Shibayama, C. et al. Type I interferon signaling in fibroblastic reticular cells prevents exhaustive activation of antiviral CD8+ T cells. Sci. Immunol. 5, eabb7066 (2020).
Google Scholar
Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell. Mol. Life Sci. 79, 191 (2022).
Google Scholar
Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516–523 (2003).
Google Scholar
Doherty, M. R. et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc. Natl Acad. Sci. USA 114, 13792–13797 (2017).
Google Scholar
Celià-Terrassa, T. et al. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis. Nat. Cell Biol. 19, 711–723 (2017).
Google Scholar
Essers, M. A. et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 458, 904–908 (2009).
Google Scholar
Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).
Google Scholar
Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535–584 (2008).
Google Scholar
Meyer, S. P., Bauer, R., Brüne, B. & Schmid, T. The role of type I interferon signaling in myeloid anti-tumor immunity. Front. Immunol. 16, 1547466 (2025).
Google Scholar
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L. & Mañes, S. Context-dependent impact of type I interferon signaling in cancer. Mol. Cancer 24, 1–16 (2025).
Google Scholar
Ko, Y.-A. et al. Blimp-1-mediated pathway promotes type I IFN production in plasmacytoid dendritic cells by targeting to interleukin-1 receptor-associated kinase M. Front. Immunol. 9, 1828 (2018).
Google Scholar
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Google Scholar
Au-Yeung, N. & Horvath, C. M. Transcriptional and chromatin regulation in interferon and innate antiviral gene expression. Cytokine Growth Factor Rev. 44, 11–17 (2018).
Google Scholar
Hardy, M. P., Owczarek, C. M., Jermiin, L. S., Ejdebäck, M. & Hertzog, P. J. Characterization of the type I interferon locus and identification of novel genes. Genomics 84, 331–345 (2004).
Google Scholar
Fung, K. Y. et al. Interferon-ε protects the female reproductive tract from viral and bacterial infection. Science 339, 1088–1092 (2013). Fung et al. identified IFNε as a novel type I IFN.
Google Scholar
Wijayarathna, R. et al. Interferon epsilon is produced in the testis and protects the male reproductive tract against virus infection, inflammation and damage. PLoS Pathog. 20, e1012702 (2024).
Google Scholar
Feng, H., Zhang, Y.-B., Gui, J.-F., Lemon, S. M. & Yamane, D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog. 17, e1009220 (2021).
Google Scholar
Savitsky, D., Tamura, T., Yanai, H. & Taniguchi, T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 59, 489–510 (2010).
Google Scholar
Wang, L. et al. The multiple roles of interferon regulatory factor family in health and disease. Signal Transduct. Target. Ther. 9, 282 (2024).
Google Scholar
Lukhele, S. et al. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. Immunity 55, 2369–2385.e10 (2022).
Google Scholar
Sarasin-Filipowicz, M. et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol. Cell. Biol. 29, 4841–4851 (2009).
Google Scholar
Mansell, A. et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating mal degradation. Nat. Immunol. 7, 148–155 (2006).
Google Scholar
Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454–465 (2007).
Google Scholar
Su, C., Hou, Z., Zhang, C., Tian, Z. & Zhang, J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol. J. 8, 1–11 (2011).
Google Scholar
Mukherjee, A., Di Bisceglie, A. M. & Ray, R. B. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J. Virol. 89, 3356–3365 (2015).
Google Scholar
Forster, S. C., Tate, M. D. & Hertzog, P. J. MicroRNA as type I interferon-regulated transcripts and modulators of the innate immune response. Front. Immunol. 6, 334 (2015).
Google Scholar
Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. Mech. Dis. 16, 167–198 (2021).
Google Scholar
Vella, V., De Francesco, E. M., Bonavita, E., Lappano, R. & Belfiore, A. IFN-I signaling in cancer: the connection with dysregulated insulin/IGF axis. Trends Endocrinol. Metab. 33, 569–586 (2022).
Google Scholar
Owen, K. L., Brockwell, N. K. & Parker, B. S. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers 11, 2002 (2019).
Google Scholar
Deonarain, R. et al. Critical roles for IFN-β in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor α. Proc. Natl Acad. Sci. USA 100, 13453–13458 (2003).
Google Scholar
Swann, J. B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540–7549 (2007).
Google Scholar
Rautela, J. et al. Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol. Res. 3, 1207–1217 (2015).
Google Scholar
Wu, Y., Wu, X., Wu, L., Wang, X. & Liu, Z. The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy. Transl. Res. 190, 51–60 (2017).
Google Scholar
Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301–1309 (2014). This paper demonstrates that chemotherapy induces a type I IFN response through viral mimicry and that a functional IFN pathway predicts response to anthracycline-based therapy.
Google Scholar
Chen, L. et al. Decreased RIG-I expression is associated with poor prognosis and promotes cell invasion in human gastric cancer. Cancer Cell Int. 18, 1–10 (2018).
Google Scholar
Zhu, H. et al. RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer. J. Exp. Clin. Cancer Res. 36, 1–11 (2017).
Google Scholar
Hou, J. et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell 25, 49–63 (2014).
Google Scholar
Poeck, H. et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14, 1256–1263 (2008).
Google Scholar
Besch, R. et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119, 2399–2411 (2009).
Google Scholar
Inao, T. et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly (I: C), on human breast cancer. Breast Cancer Res. Treat. 134, 89–100 (2012).
Google Scholar
Palchetti, S. et al. Transfected poly (I: C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells. J. Biol. Chem. 290, 5470–5483 (2015).
Google Scholar
Matsushima-Miyagi, T. et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin. Cancer Res. 18, 6271–6283 (2012).
Google Scholar
Takashima, K. et al. STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation. Biochem. Biophys. Res. Commun. 478, 1764–1771 (2016).
Google Scholar
Schadt, L. et al. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep. 29, 1236–1248.e7 (2019).
Google Scholar
Hu, J. et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature 616, 806–813 (2023). This paper demonstrates that STING is a checkpoint against the reawakening and outgrowth of dormant metastasis.
Google Scholar
Brockwell, N. K. et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. npj Precis. Oncol. 3, 21 (2019). This article revealed that the loss of IRF9 expression in TNBC is a prognostic biomarker for poor response to chemotherapy.
Google Scholar
Touati, N. et al. Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumour suppressor in breast cancer. Eur. J. Cancer 72, 95–102 (2017).
Google Scholar
Brockwell, N. K. et al. Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC. Cancer Immunol. Res. 5, 871–884 (2017).
Google Scholar
Guanizo, A. C. et al. A STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer. Nat. Immunol. 25, 2259–2269 (2024). This study outlines how STAT3 non-canonically maintains STING and that inhibition of STAT3 can enhance immune evasion and metastatic spread by silencing IFN signalling.
Google Scholar
Tian, M. et al. IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin. Nat. Commun. 11, 5762 (2020).
Google Scholar
Phan, T. G. & Croucher, P. I. The dormant cancer cell life cycle. Nat. Rev. Cancer 20, 398–411 (2020).
Google Scholar
Khoo, W. H. et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 134, 30–43 (2019).
Google Scholar
Goddard, E. T. et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell 42, 119–134.e12 (2024).
Google Scholar
Hobeika, A. C., Subramaniam, P. S. & Johnson, H. M. IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14, 1165–1170 (1997).
Google Scholar
Lan, Q. et al. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene 38, 2814–2829 (2019).
Google Scholar
Trumpp, A., Essers, M. & Wilson, A. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 10, 201–209 (2010).
Google Scholar
Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).
Google Scholar
Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080–1088 (2023).
Google Scholar
Snell, L. M., McGaha, T. L. & Brooks, D. G. Type I interferon in chronic virus infection and cancer. Trends Immunol. 38, 542–557 (2017).
Google Scholar
Terawaki, S. et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186, 2772–2779 (2011). This paper highlights that IFNα directly drives PD1 transcription in T cells.
Google Scholar
Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374–388 (2016).
Google Scholar
Jacquelot, N. et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019).
Google Scholar
Teijaro, J. Pleiotropic roles of type 1 interferons in antiviral immune responses. Adv. Immunol. 132, 135–158 (2016).
Google Scholar
Razaghi, A., Durand-Dubief, M., Brusselaers, N. & Björnstedt, M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front. Immunol. 14, 1249330 (2023).
Google Scholar
Dubrot, J. et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat. Immunol. 23, 1495–1506 (2022). This study revealed that the loss of IFN signalling sensitized tumours to ICB.
Google Scholar
Xu, B., Sun, H., Song, X., Liu, Q. & Jin, W. Mapping the tumor microenvironment in TNBC and deep exploration for M1 macrophages-associated prognostic genes. Front. Immunol. 13, 923481 (2022).
Google Scholar
Imaizumi, T. et al. Interferon (IFN)-induced protein 35 (IFI35), a type I interferon-dependent transcript, upregulates inflammatory signaling pathways by activating toll-like receptor 3 in human mesangial cells. Kidney Blood Press. Res. 41, 635–642 (2016).
Google Scholar
Xu, B. et al. IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43, 693–702 (2024).
Google Scholar
Lanng, K. R. B., Lauridsen, E. L. & Jakobsen, M. R. The balance of STING signaling orchestrates immunity in cancer. Nat. Immunol. 25, 1144–1157 (2024). This review highlights the benefits and potential detriments of STING signalling in cancer.
Google Scholar
Leonova, K. I. et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc. Natl Acad. Sci. USA 110, E89–E98 (2013).
Google Scholar
Härtlova, A. et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42, 332–343 (2015).
Google Scholar
Cheon, H., Holvey-Bates, E. G., McGrail, D. J. & Stark, G. R. PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage. Proc. Natl Acad. Sci. USA 118, e2112258118 (2021).
Google Scholar
Kim, J.-K. et al. IRF7 promotes glioma cell invasion by inhibiting AGO2 expression. Tumor Biol. 36, 5561–5569 (2015).
Google Scholar
Li, Z. et al. Interferon regulatory factor 7 promoted glioblastoma progression and stemness by modulating IL-6 expression in microglia. J. Cancer 8, 207 (2017).
Google Scholar
Tanaka, T., Murakami, K., Bando, Y. & Yoshida, S. Interferon regulatory factor 7 participates in the M1-like microglial polarization switch. Glia 63, 595–610 (2015).
Google Scholar
Wu, J., Leng, X., Pan, Z., Xu, L. & Zhang, H. Overexpression of IRF3 predicts poor prognosis in clear cell renal cell carcinoma. Int. J. Gen. Med. 14, 5675–5692 (2021).
Google Scholar
Purbey, P. K. et al. Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. Cell Rep. 43, 114289 (2024).
Google Scholar
House, I. G. et al. CRISPR–Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity. Cell Rep. 42, 113014 (2023).
Google Scholar
Watanabe, T. et al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J. Clin. Oncol. 30, 2256–2264 (2012).
Google Scholar
Chen, M. et al. cGAS–STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. npj Breast Cancer 10, 1 (2024).
Google Scholar
Magkou, C. et al. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology 60, 1125–1132 (2012).
Google Scholar
Bakhoum, S. F. & Cantley, L. C. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174, 1347–1360 (2018).
Google Scholar
Li, L. et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
Google Scholar
Li, J. et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 11, 1212–1227 (2021). This article demonstrates that ENPP1 facilitates immune evasion by hydrolysis of cGAMP, preventing cGAS–STING activation in chromosomally unstable cancer cells.
Google Scholar
Carozza, J. A. et al. ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Proc. Natl Acad. Sci. USA 119, e2119189119 (2022).
Google Scholar
Lau, W. M. et al. Enpp1: a potential facilitator of breast cancer bone metastasis. PLoS ONE 8, e66752 (2013).
Google Scholar
Wang, S. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer. Proc. Natl Acad. Sci. USA 120, e2313693120 (2023).
Google Scholar
Shang, Z., Wang, L. & Zhou, W. TREX1 exonuclease in immunity and disease. Int. Immunol. 37, 743–754 (2025).
Google Scholar
Tani, T. et al. TREX1 inactivation unleashes cancer cell STING–interferon signaling and promotes antitumor immunity. Cancer Discov. 14, 752–765 (2024). This study highlights how TREX1 inhibits STING activation by degrading cytosolic DNA and that it can be targeted to induce IFN signalling in cancer.
Google Scholar
Toufektchan, E. et al. Intratumoral TREX1 induction promotes immune evasion by limiting type I IFN. Cancer Immunol. Res. 12, 673–686 (2024).
Google Scholar
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
Google Scholar
Xing, C. et al. Targeting innate immune checkpoint TREX1 is a safe and effective immunotherapeutic strategy in cancer. Cancer Res. 85, 2858–2875 (2025).
Google Scholar
Xue, Y., Wang, Y., Ren, Z. & Yu, K. Tissue factor promotes TREX1 protein stability to evade cGAS–STING innate immune response in pancreatic ductal adenocarcinoma. Oncogene 44, 739–752 (2025).
Google Scholar
Crow, Y. J. et al. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 cause Aicardi–Goutieres syndrome at the AGS1 locus. Nat. Genet. 38, 917–920 (2006).
Google Scholar
Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. Nat. Rev. Immunol. 22, 471–483 (2022).
Google Scholar
Crossley, M. P., Bocek, M. & Cimprich, K. A. R-loops as cellular regulators and genomic threats. Mol. Cell 73, 398–411 (2019).
Google Scholar
Petermann, E., Lan, L. & Zou, L. Sources, resolution and physiological relevance of R-loops and RNA–DNA hybrids. Nat. Rev. Mol. Cell Biol. 23, 521–540 (2022).
Google Scholar
Murayama, T. et al. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 14, 468–491 (2024).
Google Scholar
Crossley, M. P. et al. R-loop-derived cytoplasmic RNA–DNA hybrids activate an immune response. Nature 613, 187–194 (2023).
Google Scholar
Gatti, V., De Domenico, S., Melino, G. & Peschiaroli, A. Senataxin and R-loops homeostasis: multifaced implications in carcinogenesis. Cell Death Discov. 9, 145 (2023).
Google Scholar
Rehwinkel, J. & Mehdipour, P. ADAR1: from basic mechanisms to inhibitors. Trends Cell Biol. 35, 59–73 (2025).
Google Scholar
Liddicoat, B. J. et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349, 1115–1120 (2015).
Google Scholar
Gannon, H. S. et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat. Commun. 9, 5450 (2018).
Google Scholar
Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43–48 (2019). This study revealed how loss of RNA-editing enzyme ADAR1 can increase cytosolic RNA sensing to ultimately sensitize tumours to ICB.
Google Scholar
Álvarez-Prado, Á. F., Hernández-Barranco, A., Rentsch, L., Costa, C. F. & Joyce, J. A. Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell Rep. 44, 116151 (2025).
Google Scholar
Hu, S.-B. et al. ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation. Mol. Cell 83, 3869–3884.e7 (2023).
Google Scholar
Guey, B. et al. BAF restricts cGAS on nuclear DNA to prevent innate immune activation. Science 369, 823–828 (2020).
Google Scholar
Ma, H. et al. Barrier-to-autointegration factor 1 protects against a basal cGAS–STING response. mBio 11, 00136-00120 (2020).
Google Scholar
Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461–465 (2017).
Google Scholar
Talens, F. & Van Vugt, M. A. Inflammatory signaling in genomically instable cancers. Cell Cycle 18, 1830–1848 (2019).
Google Scholar
Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J. Clin. Invest. 131, e139333 (2021).
Google Scholar
Lu, C. et al. DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell 39, 96–108.e6 (2021).
Google Scholar
van Vugt, M. A. & Parkes, E. E. When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers. Trends Cancer 8, 174–189 (2022).
Google Scholar
LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335–1347 (2019).
Google Scholar
Goh, P. K. et al. PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. Sci. Adv. 8, eabk3338 (2022).
Google Scholar
Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017).
Google Scholar
Ruiz-Fernández de Córdoba, B., Martínez-Monge, R. & Lecanda, F. ENPP1 immunobiology as a therapeutic target. Clin. Cancer Res. 29, 2184–2193 (2023).
Google Scholar
Pu, C. et al. Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. Nat. Commun. 16, 4793 (2025).
Google Scholar
Flowers, S. et al. A novel TREX1 inhibitor, VB-85680, upregulates cellular interferon responses. PLoS ONE 19, e0305962 (2024).
Google Scholar
Hargadon, K. M. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell. Mol. Life Sci. 80, 40 (2023).
Google Scholar
Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015).
Google Scholar
Cardenas, H. et al. Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. npj Precis. Oncol. 3, 32 (2019).
Google Scholar
Heijink, A. M. et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat. Commun. 10, 100 (2019).
Google Scholar
Yi, R. et al. ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment. Front. Genet. 11, 933 (2020).
Google Scholar
Zhang, Q. et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Cancer Res. 79, 3940–3951 (2019).
Google Scholar
Qin, Z. et al. Mutant p53 leads to low-grade IFN-I-induced inflammation and impairs cGAS–STING signalling in mice. Eur. J. Immunol. 53, 2250211 (2023).
Google Scholar
Rahnamoun, H. et al. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat. Commun. 8, 754 (2017).
Google Scholar
Zhu, K. et al. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 18, 7740–7747 (1999).
Google Scholar
Zimmerli, D. et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat. Commun. 13, 6579 (2022). This paper shows that overexpression of MYC and its co-repressor MIZ1 leads to increased binding at ISG promoters, resulting in ISG suppression in TNBC.
Google Scholar
Rajabi, H. et al. DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene 35, 6439–6445 (2016).
Google Scholar
Hagiwara, M. et al. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology 11, 2029298 (2022).
Google Scholar
Chen, X., Sandrine, I. K., Yang, M., Tu, J. & Yuan, X. MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front. Immunol. 15, 1356913 (2024).
Google Scholar
Liu, Q., Miller, L. C., Blecha, F. & Sang, Y. Reduction of infection by inhibiting mTOR pathway is associated with reversed repression of type I interferon by porcine reproductive and respiratory syndrome virus. J. Gen. Virol. 98, 1316–1328 (2017).
Google Scholar
Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer 10, e003402 (2022).
Google Scholar
Perelli, L. et al. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat. Cancer 4, 984–1000 (2023).
Google Scholar
Fountain, J. W. et al. Genetic and physical map of the interferon region on chromosome 9p. Genomics 14, 105–112 (1992).
Google Scholar
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
Google Scholar
Zhao, X. et al. Interferon-ε loss is elusive 9p21 link to immune-cold tumors, resistant to immune-checkpoint therapy and endogenous CXCL9/10 induction. J. Thorac. Oncol. 20, 1177–1236 (2024).
Google Scholar
Ganguli, P. et al. Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer. Nat. Cancer 6, 158–174 (2025).
Google Scholar
Schwendel, A. et al. Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br. J. Cancer 78, 806–811 (1998).
Google Scholar
Ichikawa, T., Suzuki, H. & Ito, H. Role of chromosomal loss in the progression of prostate cancers. Int. J. Clin. Oncol. 5, 345–354 (2000).
Google Scholar
Yamamoto, N. et al. Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncol. 39, 796–805 (2003).
Google Scholar
Kohno, T. et al. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 21, 236–243 (1998).
Google Scholar
Hasle, H., Friedman, J. M., Olsen, J. H. & Rasmussen, S. A. Low risk of solid tumors in persons with Down syndrome. Genet. Med. 18, 1151–1157 (2016).
Google Scholar
Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355, 165–169 (2000).
Google Scholar
Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. Neuropsychopharmacology 38, 23–38 (2013).
Google Scholar
Kravitz, C. J., Yan, Q. & Nguyen, D. X. Epigenetic markers and therapeutic targets for metastasis. Cancer Metastasis Rev. 42, 427–443 (2023).
Google Scholar
Falahat, R. et al. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc. Natl Acad. Sci. USA 118, e2013598118 (2021).
Google Scholar
Xia, T., Konno, H. & Barber, G. N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76, 6747–6759 (2016).
Google Scholar
Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34–45 (2019).
Google Scholar
Falahat, R. et al. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat. Commun. 14, 1573 (2023).
Google Scholar
Lee, K. -m et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol. Res. 10, 829–843 (2022).
Google Scholar
Della Corte, C. M. & Byers, L. A. Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers. Cancer Discov. 9, 16–18 (2019).
Google Scholar
Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385–401.e8 (2019). This study demonstrates that epigenetic regulator PRC2 silences key ISGs, relating to MHC-I and antigen presentation through H3K27me3 deposition in various different tumour types, highlighting a key epigenetic mechanism of immune escape.
Google Scholar
Li, Q. & Tainsky, M. A. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS ONE 6, e28683 (2011).
Google Scholar
Yamashita, M. et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 101, 1708–1716 (2010).
Google Scholar
Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067 (2013).
Google Scholar
Zheng, X. et al. Disulfiram improves the anti-PD-1 therapy efficacy by regulating PD-L1 expression via epigenetically reactivation of IRF7 in triple negative breast cancer. Front. Oncol. 11, 734853 (2021).
Google Scholar
Zeng, Y. et al. IFI44L as a novel epigenetic silencing tumor suppressor promotes apoptosis through JAK/STAT1 pathway during lung carcinogenesis. Environ. Pollut. 319, 120943 (2023).
Google Scholar
Kaminskas, E. et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11, 3604–3608 (2005).
Google Scholar
Matei, D. et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197–2205 (2012).
Google Scholar
Tsai, H.-C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430–446 (2012).
Google Scholar
Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015). This article demonstrates that low-dose DNMT inhibition targets cancer-initiating cells by inducing viral mimicry and activating an IRF7-dependent type I IFN response.
Google Scholar
Yu, Q. et al. Type I interferon controls propagation of long interspersed element-1. J. Biol. Chem. 290, 10191–10199 (2015).
Google Scholar
Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the bad with the good. Nat. Rev. Immunol. 16, 207–219 (2016).
Google Scholar
Jansz, N. & Faulkner, G. J. Endogenous retroviruses in the origins and treatment of cancer. Genome Biol. 22, 147 (2021).
Google Scholar
Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114, E10981–E10990 (2017).
Google Scholar
Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284–1300.e21 (2017).
Google Scholar
Huang, W. et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 10, 143 (2024).
Google Scholar
Alexandraki, A. & Strati, K. Decitabine treatment induces a viral mimicry response in cervical cancer cells and further sensitizes cells to chemotherapy. Int. J. Mol. Sci. 23, 14042 (2022).
Google Scholar
Xing, B., Guo, J., Sheng, Y., Wu, G. & Zhao, Y. Human papillomavirus-negative cervical cancer: a comprehensive review. Front. Oncol. 10, 606335 (2021).
Google Scholar
Guirguis, A. A. et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity. Cancer Discov. 13, 2228–2247 (2023).
Google Scholar
Wang, H. et al. Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study. Front. Med. 18, 357–374 (2024).
Google Scholar
Zhou, X. et al. Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity. Cancer Discov. 11, 3090–3105 (2021). This paper demonstrates that pharmacological activation of p53 increases ERV expression, triggering viral mimicry and type I IFN signalling to overcome immune evasion.
Google Scholar
Peterson, C. L. & Laniel, M.-A. Histones and histone modifications. Curr. Biol. 14, R546–R551 (2004).
Google Scholar
Oleksiewicz, U. et al. The roles of H3K9me3 writers, readers, and erasers in cancer immunotherapy. Int. J. Mol. Sci. 25, 11466 (2024).
Google Scholar
Timms, R. T., Tchasovnikarova, I. A., Antrobus, R., Dougan, G. & Lehner, P. J. ATF7IP-mediated stabilization of the histone methyltransferase SETDB1 is essential for heterochromatin formation by the HUSH complex. Cell Rep. 17, 653–659 (2016).
Google Scholar
Li, H. et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biol. Chem. 281, 19489–19500 (2006).
Google Scholar
Lazaro-Camp, V. J., Salari, K., Meng, X. & Yang, S. SETDB1 in cancer: overexpression and its therapeutic implications. Am. J. Cancer Res. 11, 1803 (2021).
Google Scholar
Cuellar, T. L. et al. Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia. J. Cell Biol. 216, 3535–3549 (2017).
Google Scholar
Rodriguez-Paredes, M. et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 33, 2807–2813 (2014).
Google Scholar
Sun, Y. et al. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J. Androl. 16, 319–324 (2014). This study shows that SETDB1 and members of the HUSH and KAP1 complexes mediate immune escape through inhibition of viral mimicry.
Google Scholar
Liu, L., Kimball, S., Liu, H., Holowatyj, A. & Yang, Z.-Q. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 6, 2466 (2014).
Google Scholar
Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595, 309–314 (2021).
Google Scholar
McGeary, M. K. et al. Setdb1 loss induces type I interferons and immune clearance of melanoma. Cancer Immunol. Res. 13, 245–257 (2025).
Google Scholar
Danac, J. M. C. et al. Competition between two HUSH complexes orchestrates the immune response to retroelement invasion. Mol. Cell 84, 2870–2881.e5 (2024). This work characterizes TASOR2 and the HUSH2 complex as direct epigenetic regulators of ISG induction in cancer cells.
Google Scholar
Jensvold, Z. D., Flood, J. R., Christenson, A. E. & Lewis, P. W. Interplay between two paralogous human silencing hub (HuSH) complexes in regulating LINE-1 element silencing. Nat. Commun. 15, 9492 (2024).
Google Scholar
Nusinzon, I. & Horvath, C. M. Unexpected roles for deacetylation in interferon- and cytokine-induced transcription. J. Interferon Cytokine Res. 25, 745–748 (2005).
Google Scholar
Lu, J., He, X., Zhang, L., Zhang, R. & Li, W. Acetylation in tumor immune evasion regulation. Front. Pharmacol. 12, 771588 (2021).
Google Scholar
Srinivas, N. et al. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression. J. Cancer Res. Clin. Oncol. 149, 8267–8277 (2023).
Google Scholar
Meng, J. et al. Rb selectively inhibits innate IFN-β production by enhancing deacetylation of IFN-β promoter through HDAC1 and HDAC8. J. Autoimmun. 73, 42–53 (2016).
Google Scholar
Curcio, A., Rocca, R., Alcaro, S. & Artese, A. The histone deacetylase family: structural features and application of combined computational methods. Pharmaceuticals 17, 620 (2024).
Google Scholar
Mounce, B. C., Mboko, W. P., Kanack, A. J. & Tarakanova, V. L. Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection. J. Virol. 88, 2268–2278 (2014).
Google Scholar
Salmon, J. M. et al. Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML. Cancer Discov. 12, 1560–1579 (2022).
Google Scholar
Park, S. H. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104–1116 (2017).
Google Scholar
Zhu, X., Li, Q. & Zhu, X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front. Cell Dev. Biol. 10, 1034257 (2022).
Google Scholar
Jung, I.-Y. et al. Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction. Cancer Discov. 13, 1636–1655 (2023).
Google Scholar
Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43–61 (2023). Qiu et al. demonstrate that chronic IFN signalling induces epigenetic features of ‘inflammatory memory’, further promoting ISG expression and contributing to ICB resistance.
Google Scholar
Reticker-Flynn, N. E. et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185, 1924–1942.e23 (2022).
Google Scholar
Hauschild, A. et al. Combined treatment with pegylated interferon-α-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer 113, 1404–1411 (2008).
Google Scholar
Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404.e9 (2016).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02675439 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03010176 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03937141 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04220866 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04096638 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03956680 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04147234 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05846646 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05846659 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03172936 (2022).
Qdaisat, S. et al. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nat. Biomed. Eng. 9, 1437–1452 (2025).
Google Scholar
Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647, 488–497 (2025).
Google Scholar
Gkountakos, A. et al. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients. Therap. Adv. Med. Oncol. 13, 17588359211006947 (2021).
Google Scholar
Luke, J. J. et al. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br. J. Cancer 128, 2227–2235 (2023).
Google Scholar
Gray, J. E. et al. Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 6623–6632 (2019).
Google Scholar
Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433–1442 (2020).
Google Scholar
Raninga, P. V. et al. CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers. Oncogene 44, 893–908 (2024).
Google Scholar
Wu, Z. et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin. Med. Insights Oncol. 15, 1179554921996288 (2021).
Google Scholar
Lightcap, E. S. et al. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci. Transl. Med. 13, eaba7791 (2021).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT01928576 (2024).
Hussain, M. H. et al. A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). J. Clin. Oncol. 42 (Suppl. 16), abstr. 4574 (2024).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03854474 (2026).
Domchek, S. et al. MEDIOLA: a phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours. Ann. Oncol. 27, vi377 (2016).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02734004 (2026).
Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).
Google Scholar
Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024). This study found a therapeutic benefit of blocking chronic IFN signalling in patients to restore their response to immune checkpoint inhibition.
Google Scholar
Zhao, L. et al. Role of ENPP1 in cancer pathogenesis: mechanisms and clinical implications. Oncol. Lett. 28, 590 (2024).
Google Scholar
Lee, S. Y., Kwak, M. J. & Kim, J. J. R-loops: a key driver of inflammatory responses in cancer. Exp. Mol. Med. 57, 1455–1466 (2025).
Google Scholar
Datta, R., Adamska, J. Z., Bhate, A. & Li, J. B. A-to-I RNA editing by ADAR and its therapeutic applications: from viral infections to cancer immunotherapy. Wiley Interdiscip. Rev. RNA 15, e1817 (2024).
Google Scholar
Nakahama, T. & Kawahara, Y. The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways. Int. Immunol. 35, 123–133 (2023).
Google Scholar
Baird, J. R. et al. A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression. Sci. Rep. 14, 1–17 (2024).
Google Scholar
Arimoto, K.-I., Miyauchi, S., Stoner, S. A., Fan, J.-B. & Zhang, D.-E. Negative regulation of type I IFN signaling. J. Leukoc. Biol. 103, 1099–1116 (2018).
Google Scholar
Moglan, A. M. et al. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: a systematic review. Front. Immunol. 14, 1085940 (2023).
Google Scholar
Cao, X. et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat. Commun. 12, 5866 (2021).
Google Scholar
Gao, Y. et al. CAR T cells engineered to secrete IFNκ induce tumor ferroptosis via an IFNAR/STAT1/ACSL4 axis. Cancer Immunol. Res. 12, 1691–1702 (2024).
Google Scholar
Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428 (2015).
Google Scholar
Harrer, D. C. et al. CAR triggered release of type-1 interferon limits CAR T-cell activities by an artificial negative autocrine loop. Cells 11, 3839 (2022).
Google Scholar
Cook, M. R. et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 7, 32–39 (2023).
Google Scholar
Pulliam, T. et al. Intratumoral STING agonist reverses immune evasion in PD-(L) 1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses. J. Immunother. Cancer 12, e009803 (2024).
Google Scholar
Zanker, D. J. et al. Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin. Transl. Immunol. 9, e1177 (2020).
Google Scholar
Boukhaled, G. M. et al. Peripheral CD4 T cell resistance to type I interferon defines outcome of PD1 blockade therapy in human cancer. J. Immunol. 208, 180.103 (2022).
Google Scholar
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018).
Google Scholar
Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).
Google Scholar
Shaw, A. C., Goldstein, D. R. & Montgomery, R. R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875–887 (2013).
Google Scholar
Ghosh, S. & Klein, R. S. Sex drives dimorphic immune responses to viral infections. J. Immunol. 198, 1782–1790 (2017).
Google Scholar
Conforti, F. et al. Sex hormones, the anticancer immune response, and therapeutic opportunities. Cancer Cell 43, 343–360 (2025).
Google Scholar
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P. & McAllister, S. S. Ageing, immune fitness and cancer. Nat. Rev. Cancer 25, 848–872 (2025).
Google Scholar
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10 (2025).
Google Scholar
Wang, L. & Tang, D. Immunosenescence promotes cancer development: from mechanisms to treatment strategies. Cell Commun. Signal. 23, 128 (2025).
Google Scholar
Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target. Ther. 8, 239 (2023).
Google Scholar
Fane, M. & Weeraratna, A. T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 20, 89–106 (2020).
Google Scholar
Nguyen, T. Q. T. & Cho, K. A. Targeting immunosenescence and inflammaging: advancing longevity research. Exp. Mol. Med. 57, 1881–1892 (2025).
Google Scholar
Lee, K. A., Flores, R. R., Jang, I. H., Saathoff, A. & Robbins, P. D. Immune senescence, immunosenescence and aging. Front. Aging 3, 900028 (2022).
Google Scholar
Stout-Delgado, H. W., Yang, X., Walker, W. E., Tesar, B. M. & Goldstein, D. R. Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation. J. Immunol. 181, 6747–6756 (2008).
Google Scholar
Panda, A. et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184, 2518–2527 (2010).
Google Scholar
Jing, Y. et al. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum. Immunol. 70, 777–784 (2009).
Google Scholar
Zhou, B., Lawrence, T. & Liang, Y. The role of plasmacytoid dendritic cells in cancers. Front. Immunol. 12, 749190 (2021).
Google Scholar
Shodell, M. & Siegal, F. P. Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing. Scand. J. Immunol. 56, 518–521 (2002).
Google Scholar
Canaday, D. H. et al. Influenza-induced production of interferon-alpha is defective in geriatric individuals. J. Clin. Immunol. 30, 373–383 (2010).
Google Scholar
Molony, R. D. et al. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal. 10, eaan2392 (2017).
Google Scholar
Renshaw, M. et al. Cutting edge: impaired toll-like receptor expression and function in aging. J. Immunol. 169, 4697–4701 (2002).
Google Scholar
Feng, E., Balint, E., Poznanski, S. M., Ashkar, A. A. & Loeb, M. Aging and interferons: impacts on inflammation and viral disease outcomes. Cells 10, 708 (2021).
Google Scholar
Sceneay, J. et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discov. 9, 1208–1227 (2019). This study demonstrates that the TME in aged mice and patients with TNBC exhibit decreased IFN signalling and antigen presentation, resulting in resistance to ICB.
Google Scholar
Wong, C. P., Magnusson, K. R. & Ho, E. Aging is associated with altered dendritic cells subset distribution and impaired proinflammatory cytokine production. Exp. Gerontol. 45, 163–169 (2010).
Google Scholar
Gigley, J. P. & Khan, I. A. Plasmacytoid DC from aged mice down-regulate CD8 T cell responses by inhibiting cDC maturation after encephalitozoon cuniculi infection. PLoS ONE 6, e20838 (2011).
Google Scholar
Sinicrope, F. A. Increasing incidence of early-onset colorectal cancer. N. Engl. J. Med. 386, 1547–1558 (2022).
Google Scholar
Ailawadi, S., Kaelber, D. C. & Elangovan, A. Early-onset colorectal cancer: a review of current insights and a call for action. Biomedicines 13, 1572 (2025).
Google Scholar
Shiels, M. S. et al. Trends in cancer incidence and mortality rates in early-onset and older-onset age groups in the United States, 2010–2019. Cancer Discov. 15, 1363–1376 (2025).
Google Scholar
Lima, S. M., Kehm, R. D., Swett, K., Gonsalves, L. & Terry, M. B. Trends in parity and breast cancer incidence in US women younger than 40 years from 1935 to 2015. JAMA Netw. Open 3, e200929 (2020).
Google Scholar
di Martino, E. et al. Incidence trends for twelve cancers in younger adults — a rapid review. Br. J. Cancer 126, 1374–1386 (2022).
Google Scholar
Kehm, R. D. & Terry, M. B. Early onset cancer trends and the persistently higher burden of cancer in young women. Oncologist 30, oyaf084 (2025).
Google Scholar
Yang, Y. et al. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nat. Commun. 12, 6757 (2021).
Google Scholar
Weeden, C. E., Hill, W., Lim, E. L., Grönroos, E. & Swanton, C. Impact of risk factors on early cancer evolution. Cell 186, 1541–1563 (2023).
Google Scholar
Zhang, S. et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct. Target. Ther. 9, 149 (2024).
Google Scholar
Kugel, C. H. III et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347–5356 (2018).
Google Scholar
Mauri, G. et al. Early-onset cancers: biological bases and clinical implications. Cell Rep. Med. 5, 101737 (2024).
Google Scholar
Erbe, R. et al. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 37, 110033 (2021).
Google Scholar
Baruch, K. et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89–93 (2014).
Google Scholar
Benayoun, B. A. et al. Remodeling of epigenome and transcriptome landscapes with aging in mice reveals widespread induction of inflammatory responses. Genome Res. 29, 697–709 (2019).
Google Scholar
Gilbert, C. et al. Age-related expression of IFN-λ1 versus IFN-I and beta-defensins in the nasopharynx of SARS-CoV-2-infected individuals. Front. Immunol. 12, 750279 (2021).
Google Scholar
Patel, M. V., Hopkins, D. C., Barr, F. D. & Wira, C. R. Sex hormones and aging modulate interferon lambda 1 production and signaling by human uterine epithelial cells and fibroblasts. Front. Immunol. 12, 718380 (2021).
Google Scholar
Smith, U., Li, Q., Rydén, M. & Spalding, K. L. Cellular senescence and its role in white adipose tissue. Int. J. Obes. 45, 934–943 (2021).
Google Scholar
Karakasilioti, I. et al. DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria. Cell Metab. 18, 403–415 (2013).
Google Scholar
Chan, C. C. et al. Type I interferon sensing unlocks dormant adipocyte inflammatory potential. Nat. Commun. 11, 2745 (2020).
Google Scholar
Cao, L. B. et al. Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast carcinogenesis. J. Mol. Cell Biol. 15, mjad047 (2024). This study shows that ERα acts as a negative regulator of IFN signalling by promoting expression of H2A.Z and restricting ISGF3 complex activity.
Google Scholar
Laffont, S. et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-α production of plasmacytoid dendritic cells from women. J. Immunol. 193, 5444–5452 (2014).
Google Scholar
Panchanathan, R., Shen, H., Zhang, X., Ho, S. M. & Choubey, D. Mutually positive regulatory feedback loop between interferons and estrogen receptor-alpha in mice: implications for sex bias in autoimmunity. PLoS ONE 5, e10868 (2010).
Google Scholar
Hughes, G. C., Thomas, S., Li, C., Kaja, M.-K. & Clark, E. A. Cutting edge: progesterone regulates IFN-α production by plasmacytoid dendritic cells1. J. Immunol. 180, 2029–2033 (2008).
Google Scholar
Shen, H. et al. Gender-dependent expression of murine Irf5 gene: implications for sex bias in autoimmunity. J. Mol. Cell Biol. 2, 284–290 (2010).
Google Scholar
Panchanathan, R., Liu, H. & Choubey, D. Expression of murine Unc93b1 is up-regulated by interferon and estrogen signaling: implications for sex bias in the development of autoimmunity. Int. Immunol. 25, 521–529 (2013).
Google Scholar
Panchanathan, R., Shen, H., Bupp, M. G., Gould, K. A. & Choubey, D. Female and male sex hormones differentially regulate expression of Ifi202, an interferon-inducible lupus susceptibility gene within the Nba2 interval. J. Immunol. 183, 7031–7038 (2009).
Google Scholar
Kovats, S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 294, 63–69 (2015).
Google Scholar
Behjati, S. & Frank, M. The effects of tamoxifen on immunity. Curr. Med. Chem. 16, 3076–3080 (2009).
Google Scholar
Zhang, Y., Tan, X. & Tang, C. Estrogen-immuno-neuromodulation disorders in menopausal depression. J. Neuroinflamm. 21, 159 (2024).
Google Scholar
Hong, C. C. et al. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res. Treat. 139, 477–488 (2013).
Google Scholar
Segovia-Mendoza, M. & Morales-Montor, J. Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology. Front. Immunol. 10, 348 (2019).
Google Scholar
Kamada, M. et al. Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. Gynecol. Obstet. Invest. 52, 82–88 (2001).
Google Scholar
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M. S. & Catalano, A. Targeting breast cancer: an overlook on current strategies. Int. J. Mol. Sci. 24, 3643 (2023).
Google Scholar
Semiglazov, V. et al. Immunology and immunotherapy in breast cancer. Cancer Biol. Med. 19, 609–618 (2022).
Google Scholar
Lee, H. J. et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget 7, 30119–30132 (2016).
Google Scholar
Wang, X. et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839–850 (2017).
Google Scholar
Liang, Y. et al. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat. Commun. 9, 4586 (2018).
Google Scholar
Chung, W. et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 8, 15081 (2017).
Google Scholar
Sobral-Leite, M. et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology 7, e1509820 (2018).
Google Scholar
Lindner, D. J., Kolla, V., Kalvakolanu, D. V. & Borden, E. C. Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol. Cell. Biochem. 167, 169–177 (1997).
Google Scholar
Mostafa, A. A. et al. Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells. PLoS ONE 9, e87377 (2014).
Google Scholar
Sas, L. et al. The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res. 14, 212 (2012).
Google Scholar
Zhao, T. et al. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat. Immunol. 8, 592–600 (2007).
Google Scholar
Iwanaszko, M. & Kimmel, M. NF-κB and IRF pathways: cross-regulation on target genes promoter level. BMC Genom. 16, 307 (2015).
Google Scholar
Nehra, R. et al. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 24, 2040–2055 (2010).
Google Scholar
Hühn, D. et al. Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells. Mol. Oncol. 16, 148–165 (2022).
Google Scholar
Devanaboyina, M. et al. NF-κB signaling in tumor pathways focusing on breast and ovarian cancer. Oncol. Rev. 16, 10568 (2022).
Google Scholar
Ning, Y. et al. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol. Cancer Ther. 9, 1274–1285 (2010).
Google Scholar
Baratchian, M. et al. H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Proc. Natl Acad. Sci. USA 119, e2114324119 (2022).
Google Scholar
Chesner, L. N. et al. Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. Cancer Discov. 15, 481–494 (2025).
Google Scholar
Alizadeh-Ghodsi, M. et al. Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer. Cancer Res. Commun. 2, 706–724 (2022).
Google Scholar
Hickey, T. E. et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat. Med. 27, 310–320 (2021).
Google Scholar
Ren, J., Hou, Y. & Wang, T. Roles of estrogens on myeloid-derived suppressor cells in cancer and autoimmune diseases. Cell Mol. Immunol. 15, 724–726 (2018).
Google Scholar
Huang, H. et al. The immunomodulatory effects of endocrine therapy in breast cancer. J. Exp. Clin. Cancer Res. 40, 19 (2021).
Google Scholar
Svoronos, N. et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov. 7, 72–85 (2017).
Google Scholar
Li, S. et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat. Immunol. 17, 241–249 (2016).
Google Scholar
Ghosh, M. et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39, 494–508.e5 (2021).
Google Scholar
Reeves, E., Islam, Y. & James, E. ERAP1: a potential therapeutic target for a myriad of diseases. Expert. Opin. Therap. Target. 24, 535–544 (2020).
Google Scholar
Katlinskaya, Y. V. et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 15, 171–180 (2016).
Google Scholar
Bradley, S. D. et al. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol. Res. 3, 602–609 (2015).
Google Scholar
Tas, F. & Erturk, K. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. Cancer Chemother. Pharmacol. 84, 521–526 (2019).
Google Scholar
Mayall, J. R. et al. Interferon-epsilon is a novel regulator of NK cell responses in the uterus. EMBO Mol. Med. 16, 267–293 (2024).
Google Scholar
Barriga, F. M. et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat. Cancer 3, 1367–1385 (2022).
Google Scholar
